AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), BRAF (B-raf proto-oncogene), CHEK2 (Checkpoint kinase 2), CTNNB1 (Catenin (cadherin-associated protein), beta 1)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), BRAF (B-raf proto-oncogene), CHEK2 (Checkpoint kinase 2), CTNNB1 (Catenin (cadherin-associated protein), beta 1), DDR2 (Discoidin domain receptor 2), EGFR (Epidermal growth factor receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FGFR4 (Fibroblast growth factor receptor 4), FLT3 (Fms-related tyrosine kinase 3), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), mTOR (Mechanistic target of rapamycin kinase)